You should consider the offer document and the general risk warning before investing.
You are currently viewing PledgeMe Australia, would you like to view PledgeMe New Zealand instead?

Yes, go to PledgeMe New Zealand No thanks

Medicinal Organic Cannabis Australia (MOCA) Pty Ltd

By Alessandro Sorbello

PledgeMe.Investment



AU $120,250 pledged


35 people pledged


Closed


AU $100,000 minimum target


Min

AU$100,000

Max

AU$500,000

100 100% Complete

Pledges will only be confirmed if the target is reached by: 21/10/2020 at 6:00 PM (AEST)

Make a Pledge

About

Medicinal Organic Cannabis Australia (MOCA) Pty Ltd

Medicinal Organic Cannabis Australia (MOCA) Pty Ltd (ACN: 619 709 278) are offering up to 500,000 fully-paid ordinary shares at $1 per share to raise a maximum of $500,000. This Offer is made under the CSF regime in Part 6D.3A of the Corporations Act 2001 (Corporations Act).

The general public in Australia can buy up to $10,000 worth of shares in this company, as part of the new equity crowdfunding legislation (Note: there is no cap on how much Sophisticated Investors can invest). Please make sure to read the risk warning statementoffer document, and understand the Cooling-Off rights. Instructions on how to register to invest and pledge are here.

 

Whats in this for you, the investor?

In this proposal, you will find an opportunity to invest in a highly profitable business model designed to bring high yield dividends to YOU the investor. Our focus is in developing rapid and significant capital growth with a view to going public in the next 2/3 years. Our plan is to dominate the organic cannabis industry in Australia. 

What makes us different and why we will succeed!

Investing in MOCA means backing a company that has a unique delivery model to bring cannabis medication to the broader market, making it accessible to the largest possible customer base. Our operational structure and product sourcing allows MOCA to disrupt the industry in Australia by bringing best quality products at the lowest prices. We do this through our low operating costs, agility to respond to a rapidly changing market dynamic and leveraging state of the art third party logistics fulfilment systems. Backing MOCA is backing a winning team dedicated to success.

Letter from the Co-founder, Alessandro Sorbello

Dear friends and potential investors,

We are very excited about the information we are about to share with you. Medicinal Cannabis is a booming industry and it's still in its infancy.

And now a little about how we got to where we are and our plans for ongoing profitable growth.

Health, wellbeing and quality of life has been a central theme in my life and in recent years, much more so. When my father was in his 20’s he suffered from a major head trauma as a result of a motorcycle accident. This led to mental health issues late in his life. As one of his principal carers during the last ten years of his life, it was saddening to witness firsthand the deterioration of his memory and many other mental faculties.

It was not until after his passing in 2014, that I came to learn that the United States government had patented cannabis as a neuroprotectant in the 1980’s. The patent claims: “...cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia”.

My father's passing left me wondering how cannabis may have been able to help him and increase his quality of life, in particular, late in his life when his dignity began to suffer. I wondered why the medication that would have surely helped him was not available.

When the Australian Government announced in 2016 that it was changing legislation regarding cannabis, I started to delve into it much further. I learned that cannabis is an ancient medicine with well over 7000 years of history. In the 21st century, after a hiatus of over 70 years due to prohibition, it has once again become a recognised medicine, rapidly gaining in popularity around the world because of its effectiveness.

As a PhD candidate, I am used to conducting research and very early on I learned a key fact regarding cannabis. Something so startling, that it would set my destiny on a new and exciting path and I owe it all to an Israeli scientist named Raphael Meschulam.

Professor Meschulam discovered in 1990 that humans and almost all animals have an endocannabinoid system (ECS) that responds favourably to cannabis. The ECS is considered among the most important systems in the human body and is responsible for maintaining and regulating health. Reference

The importance of this information captured my attention so much, that I dove into learning everything I could about the ECS and how cannabis functions as a medicine. Armed with this information and glimpsing what this would mean for humanity, my partner Emanuela and I committed to revolutionise our lives and our professional activities. We both recognised that this was the opportunity we were looking for.

As company directors and founders, Emanuela and I both have a long history of building teams and organisations to set new boundaries on how ethical business is conducted. I spent 11 years with the Italian Ministry of Foreign Affairs as a Cultural Attache’. In 2010 I was honored to be awarded a Knighthood by the President of Italy for my work on building international trade between Italy and Australia. Emanuela spent numerous years as an advisor to the Department of Justice in Queensland, reporting directly to the Minister.

Emanuela and I placed our focus entirely on the emerging medical cannabis industry. We undertook intensive learning and study to grasp the potential of the healing plant and the business opportunity it presented.

Analysts indicate that Australia’s cannabis market is expected to surpass the US$1.5 billion mark by 2025, making it the largest legal cannabis market in the Oceania region. Reference. International projections indicate the global cannabis market size will reach US$97.35 billion by the end of 2026, up from US$10.6 billion in 2018. Reference.

With our vision becoming clearer each week and month, and with the business world confirming the enormous and rapid growth of the cannabis market worldwide, we started assembling a larger team. To build our advisory board, we enlisted Dr Arno Hazekamp, one of the world's leading experts on medical cannabis research. Next, we engaged Dr Eliane Karsaklian to our advisory board, a senior professor at the Sorbonne University who is an expert of international business & negotiations for over 20 years.

This combination of scientific expertise and extensive international business experience formed the basis of our company, Medicinal Organic Cannabis Australia. We like to call it MOCA. We chose to incorporate the word organic into the name of the company because we believe that pesticides and herbicides have no place in medicine.

The cornerstone philosophy of MOCA is ‘People, Planet, Profit’ and one of MOCA’s key metrics for success is our ability to make cannabis medication affordable. We believe that a plant based medicine should be available to everyone.

Over the past three years since MOCA was established, we have taken many important and exciting steps forward toward our vision and our goals.

Today, MOCA is an Australian Government licenced medical cannabis importer, exporter and wholesaler. The Company’s licences were awarded by the Australian State and Federal Governments in 2018. These licences allow the Company to manufacture, import and supply by wholesale medical cannabis products. Our Government approved client base consists of hospitals, pharmacies and medical practitioners. The Company's complete product range is approved by the Therapeutic Goods Administration (TGA) and is ready for practitioners to prescribe to patients in Australia. Our approved medical cannabis product range includes capsules, sublingual oils, isolates, vape pens and whole cannabis flowers. We currently hold all necessary permits from the Office of Drug Control (ODC) to import medical cannabis products into Australia.

Through our ‘hands on’ approach, we have created an innovative way to lower the product cost to patients by up to 30% of current retail prices. We have also been working directly with cultivators to positively influence and improve the methodology of the organic farming practices.

We are very proud of what we have achieved so far and are very excited about the journey that’s unfolding before us, that continually brings our vision to existence. We trust that you will enjoy our presentation and decide to own a piece of MOCA, to continue this journey with us.

We are at a new beginning in plant-based medicine.

Thank you and warm regards

Alessandro

 

 

 

Our products

MOCA offers a wide range of organic medical cannabis products imported from the United States and Europe with shipments due to arrive in Australia in November/December 2020. The range of products includes organic capsules, oils, tinctures and cannabis flowers with THC, CBD and a combination of both. The Company is licenced to import, export and wholesale the full spectrum of medical cannabis products including THC and CBD products. Overall, MOCA meets the highly regulated medical cannabis needs of Australian regulators and International patients, medical doctors, pharmacies and hospitals.

Our CBD products are made from 100% organically grown, non-GMO Hemp. Cultivated premium grade, pesticide-free, heavy metal-free, solvent-free, gluten-free, THC-free, FDA-registered, cGMP-certified, ISO 9001, ISO 17025, industrial hemp registered, and 3rd-Party Tested.

MOCA holds permits from the Office of Drug Control to import our full  range of 21 products including: 

Products

Concentration and Size

CBD Oil Capsules 

750mg

Hemp and MCT Oil

500mg, 1000mg, 1500mg

CBD Flowers

5 grams, 10 grams, 28 grams

THC & CBD Flowers

10grams

MOCA CBD Capsules Full Spectrum

25mg

MOCA CBD DROPS 

1000mg, 1500mg, 3500mg, 5000mg

MOCA CBD Isolates

99% and 99.88% CBD

Vape Pens

5ml

CBD Tinctures

60mg, 120mg, 300mg, 500mg

 

In order to ensure continuity of supply in potential times of limitations on product movement, we have multiple suppliers for each of our products. In the event of disruption in the supply chain, we are able to import our products, made to our specifications from different manufacturers and geographical locations. 


MOCA has developed a new product sourced directly from growers in the Mediterranean that has the potential to reduce costs to patients by up to 30%.



The product range is all organic and naturally produced and takes advantage of the ‘entourage effect’ by using all the cannabinoids in the whole plant. At this stage, we are keeping the technical details confidential to ensure we can leverage the product to be first movers in the Australian industry.

 

 

Our business model

MOCA’s business model is built on quality, agility, market responsiveness and economy of scale in bringing our products to market. Our team comprises dedicated professionals with over 40 years’ experience in the cannabis industry and the Company is committed to educating consumers and health professionals on the use of medical cannabis.

Our business model is very simple and is described in two parts. We: 

1) Import and wholesale our products

2) Source, control production and manufacture high quality products.  

 

 

1) Importing and wholesaling our products 

Part one includes all the activities associated with importing. selling and distribution of our products and reaching customers to transacting a sale. In this phase of product distribution another factor comes into play. As a wholesaler our facility  breaks products down into smaller units, which are then sold to different medical retailers.

This process is handled for MOCA by a contracted, specialised pharmaceutical grade third party supplier which means we have lower costs. 

In addition to critical sales and marketing skills, we believe MOCA has the operational skills necessary for running the Company. Our finance and business management skills and experience give us the  ability to handle the "back end" that go on behind the scenes, like receiving customer orders and providing high levels of customer service. We are technology driven and have automated many of the processes with third party digital software for accounting, ordering and managing inventory.

 

 

2) Source, control production and manufacture high quality products. 

The cornerstone in our distribution cycle is the basic flow of product from manufacturer to distributor to customer. As a wholesale distributor, our role on the supply chain involves matching up manufacturers  and customers by obtaining quality products at a reasonable price and then selling them to the companies that need them.

Part two comprises all the manufacturing and sourcing phases. This includes all the activities associated with making and designing our products, including purchasing raw materials, manufacturing, and so on. 

In this phase, we use our team's expert knowledge of the industry to work with growers and cultivators and choose which crops and products we are interested in acquiring. 

Our focus on the ‘Triple Bottom Line’ of ‘People, Planet, Profit’ means that we work with designers, growers, scientists and manufacturers aligned to our principles to create our organic range of cannabis medicines.

Our directors work hands on and ‘boots on the ground’  to select suppliers that meet our Triple P processes. These cultivators grow organically and ethically and have developed trust in our relationship. This means that we are not only a reliable source for customers but can be a reliable source for the industry. 

Some of the most affordable products for retail sales come from other countries where product development and manufacturing is more advanced than Australia. Importing is the best option for getting the products that meet our criteria of high quality and affordable prices. By dealing with multiple suppliers we can buy products at their best to sell directly to the medical industry at a good margin.

Since obtaining our Federal licences, the Company has concentrated on developing high quality, organic products to supply under the MOCA brand. Our business intelligence team, in conjunction with the University of Paris (Sorbonne) conducted a 12 month long extensive consumer survey to understand patient needs. In 2019/2020 we extended this ongoing research by working with medical practitioners in Australia to understand how doctors are prescribing cannabis. Our scientific research team developed our products based on client and prescriber requirements.  

Now that we have all of our licences, we are ready to expand our importation into Australia to our complete range of high quality organic products specifically designed to meet growing medical practitioners prescribing demand.  

 

 

Our team

Company Directors 

Alessandro Sorbello

Alessandro Sorbello PhD candidate (Managing Director) has been a company director for over 30 years. He holds a Masters degree in Business and is completing his PhD on Consumer Behaviour. His roles have included Secretary General of the Italian Chamber of Commerce and Cultural Attaché to the Italian Ministry of Foreign Affairs.  He is an international award winning researcher and publisher. Read More 

Emanuela Ispani

Emanuela Ispani  BE (Electronics) (Director) holds a degree in electronics engineering, specialised in Robotics.  Her expertise includes business management, strategy development, research, and business planning. She has extensive experience in working with both State and Federal Government reporting to the Minister. Her work within the Information Technology industry, at national and international levels has been a progression from business consulting to project/program management. Read More 

Scientific Advisory Team

Arno Hazekamp

Head of Scientific Research - Dr Arno Hazekamp PhD is an internationally acclaimed cannabis researcher biochemist, and former Head of Research and Education at Bedrocan BV - the official grower of medicinal cannabis in the Netherlands. His PhD thesis was focused on the medicinal use of cannabis, and the practical issues that prevent it from becoming part of modern medicine. He is a board member of the International Association for Cannabinoid Medicines (IACM), an active international lecturer and medicinal cannabis advocate. Read More 

Eliane Karsaklian

Head of International Marketing - Dr Eliane Karsaklian PhD is an internationally known speaker, award-winning researcher, and professor who directs the Master Program for International Negotiation at Université Sorbonne in Paris. She has led several companies including Discovery Channel, Gucci, Sanofi-Aventis and Walt Disney World to build relationships that created or expanded their markets. She has published several articles and books in the field of international business more recently Sustainable Negotiation. Read more

Alessandra Scano

Scientific Research - Dr. Alessandra Scano PhD holds a Master in Science degree in Pharmaceutical Chemistry and Technology and a PhD in Chemical Science. She also has a  Master in Science in Cellular and Molecular Biology at University of Cagliari. She spent one year (2009) as Postdoc at Materials and Surface Science Institute (MSSI), University of Limerick (Ireland). Read More

Guido Ennas

Scientific Research -Professor Guido Ennas PhD. is the Deputy Director of the Biology and Pharmacy Faculty, and Leader of the Micro and Nanostructured Materials Research Group, being a specialist in design, synthesis, characterization (structural, morphological and thermal) and developing of inorganic, nanostructured micro and mesoporous materials. Read More

Finance

 Joe Catalano

Head of Finance - Joe Catalano Bachelor of Commerce Joe is the director and Founding Partner of CNS Partners the company has 4 directors and 10 team members. As founding partner, Joe has been involved from the early humble beginnings, to the successful, multi-faceted organisation his clients currently enjoy. Joe has a Bachelor of Commerce, a Graduate Diploma of Chartered Accounting (CA), is a registered tax agent and holds a public practice certificate. Read More

 

Our Growth Plans

Over the next three years, the Company will operate on a staged approach to leverage its licences and continue to bring a variety of federally approved medical cannabis products into Australia.

Stage one is manufacturing and importing our approved range of products to sell to a rapidly growing market. We plan to leverage the very recent changes to legislation to take rapid advantage by marketing the 4 products in our product range that meet the new regulations and that are already approved by the TGA. 

Manufacturing our Medicine

Stage two is manufacturing our newest range of whole plant infusion products. We believe this is a game changer for the industry as we have developed a product that will significantly reduce the cost of the medicine. We have access to a large supply of organically grown whole plant biomass that we can acquire at excellent prices. We plan to flood the Australian market with this new product in late 2020. To give you some idea of how excited we are by this new product, CBD flowers on the wholesale market in Australia sell to the end user for approx $120 for 10 grams.

Our new product could be on the market for $120 for 100 grams. 

We believe this is a true game changer. 

 

 

Stage three is operationalizing our cultivation facility in Italy. The Company has signed a 15 year lease agreement for 18,000m2 of high quality organic agricultural land. The property has a purpose built 6900m2 Greenhouse ideal for organic cannabis cultivation. Our approved subsidies  allow MOCA to purchase fuel necessary to run equipment at 50% of retail prices.  These subsidies allow the Company to produce cannabis biomass at substantially reduced costs in comparison to cultivation  in Australia.  We anticipate being able to produce over 10,000 kgs of organic whole plant biomass, rich in CBD for importation into Australia in 2021. 

At this stage we will cultivate cannabis rich in CBD and complete the entire cycle: cultivation, manufacturing, importing and wholesaling. 

Our import licences enable us to wholesale our cannabis products to pharmacies, hospitals and licenced medical professionals. Our export licence enables the Company to sell products to licenced buyers around the world.

Our potential import sales for 2020-2023

Our average unit will cost $32.00 to produce, and wholesale at $115.00. 

 

Expand Digital Marketing

Our marketing focus is online and MOCA has on average over 35,000 visitors per month to its online presences. Our Google My Business performance of 25,900 views in a 28 day period. We will be expanding the site with our range of products and promoting our partner pharmacies and medical practitioners. We intend to expand our marketing online by further developing our online brands which include the MOCA website on www.medicinalorganiccannabis.org. MOCA has developed an online sales platform (full product range and pricing to be added when products are ready for purchase) for sales directly to the pharmaceutical industry.

We have a basic presence on our other websites which include https://www.OrganicCBD.com.au and this will be expanded to include our product range. The site will be optimised for SEO and will offer the entire suite of services offered on the MOCA site. 

Our visibility on  the major search engines is very high as you can see from the Google search results for ‘organic cannabis Australia’. Our focus will be on expanding the online presences across all sites including social media. The Company will develop secondary search engines results including medicinal organic cannabis on Yahoo (first page listing)

These are a small selection of our brand building online that MOCA has been developing over the past 3 years. 

Our digital strategy is high on our priorities to leverage our current visibility and attract new patients, medical practitioners and pharmacies.

MOCA has a definite focus on a global market, the Company has already participated in 2 international tenders to supply markets in Italy and Barbados. Our approach to penetrating national and international markets leverages our experience in online marketing. The Company enjoys the very high visibility online via our numerous digital marketing channels as you will see later in this presentation. In effect, we receive several requests from practitioners and pharmacies each day for supply of our products.

 

 

Our Capital Structure

As at the date of this CSF offer document, the Company has 15,010,000 Class A shares. As set out in Table 1 below, the 15,000,000 shares are held by two of the Company’s Executive Directors, Mr Alessandro Sorbello (Managing Director) and Ms Emanuela Ispani (Executive Director), and Mr Peter Cupples and Ms Lisa Cornish also have 5,000 shares each.

 

 

Our Risks

An investment in the Company should be seen as high-risk and speculative. A description of the main risks that may impact our business is below. Investors should read this section carefully before deciding to apply for shares under the Offer. There are also other, more general, risks associated with the Company (for example, risks relating to general economic conditions or the inability to sell our shares). We have worked hard to mitigate our risks: 

 

Licencing and government approvals 

The Company has already obtained all the necessary import/export licences and licences to sell prohibited drugs approvals from the Office of Drug Control (ODC). We currently hold licences from New South Wales Health to store and handle all cannabis based medications and have an approved set of protocols to manage logistics, warehousing and distribution. The ODC has already issued MOCA with import permits to bring our products into Australia. Starting with the products that are most in demand and taking advantages of the recent changes to legislation regarding CBD, we will import products to match these profiles (e.g. capsules, vapes, cbd oils)

TGA Approvals 

The Therapeutic Goods Administration (TGA) must approve all medical cannabis products in Australia. Currently MOCA has 21 products approved by the TGA for prescription to patients by medical practitioners.

Customer Base

Numerous medical practitioners, hospitals and pharmacies seeking our products. These clients are awaiting our medicines to be imported for prescribing to their patients 

Patient Intake Program

The Company has a patient intake program whereby patients contact MOCA seeking our medications and assistance in obtaining access to medical practitioners.

 

Main risks

There are still many potential risks to the business that include: 

Increased Competition 

The cannabis industry in Australia and internationally is growing rapidly with increased competition entering into the market.  Local production is ramping up and in the coming years will produce a significant output of plant biomass ready for transformation into finished products. MOCA is offsetting some of this risk by working with international markets for supply and in the second instance for export from Australia. The Company is currently working in the European market that has a potential customer audience of 740 million people

Market Growth Plateaus

Medical cannabis growth in Australia has risen consistently and access has become easier for patients. In the future, growth in the marketplace may stabilise and growth may stall. MOCA offsets this risk by diversifying our potential audience with differentiated price points of organic and non-organic products.

Present Sources of Product Supply

MOCA has supply agreements with OrganicMarijuana.com, an international wholesaler and cultivator of organic cannabis as well as with organisations in the United States, Jamaica, Italy and Canada.

We have supply agreements with multiple suppliers in the event of disruption to our supply chain. These suppliers are located in various countries, limiting the risk of supply disruption.  Our intention is to keep a supply of 1500 units of stock in Australia at all times, in the event that there is a disruption to supply due to Covid 19 or other potential threats. This supply will ensure continuity of stock in the event that we are required to ramp up manufacture from another supplier. 

Future competition

The Australian medical cannabis industry is still in its infancy and local demand will continue to outweigh local supply for many years to come. Given the variations of cannabis-based medications and the increase in demand for organic medicine, MOCA is well positioned to capitalise on the growing market in Australasia 

Import restrictions affecting products

Medical cannabis currently falls under both schedule 4 and schedule 8 classifications by the TGA and the Office of Drug Control and is a highly regulated medicine. MOCA is one of only 26 companies licenced to import cannabis-based products into Australia (3). Obtaining licences for import and export in Australia is costly and approvals can take up to 18 months.   Of the 100 products approved by the Federal government, MOCA has 21 products already approved. 

Growth in competition from black market products

In the past, many patients have turned to the illegal black market to obtain cannabis for treatment of medical conditions, due to the long approval times and the high cost of legally available products. The changes in legislation and the increased supply in legal options has seen rapid growth in demand.   

Cashflow

There is a risk that the company may not be able to access capital. This could affect cash flow issues as MOCA grows. Our business strategy to mitigate this risk is to import and sell our products immediately to establish a revenue stream. Our Aim is that ongoing sales from continually arriving imported stock will generate the cashflow necessary to grow and keep the company secure.

 

 

 

 

Our Offer

The Company is offering up to 500,000 shares at an issue price of $1 to raise up to $500,000. 

Key information relating to the offer is set out below.

_____________

Term Details 

_____________

Shares: Fully paid ordinary shares

Price: $1 per share

Minimum Subscription: $100,000

Maximum Subscription: $500,000

Opening Date: 21st September 2020

Closing Date: 21st October 2020

_____________

 

A description of the rights associated with the shares is set out in Section 3.3 of our offer document. To participate in the Offer, you must submit a completed application form via the Intermediary’s platform. The Intermediary’s website provides instructions on how to apply for shares under the Offer. 

 

The Intermediary must close the Offer early in certain circumstances. For example, if the Maximum Subscription is reached, the Offer must be closed. If the Minimum Subscription is not reached or the Offer is closed but not completed, you will not be charged for your pledge. Investors may withdraw their application during the Cooling-off Period. 

 

Further information on investor cooling-off rights can be found in Section 4 of this CSF offer document. 

 

The Offer is not underwritten.

 

 

Information about Investor Rights

4.1 Cooling-off rights 

You have the right to withdraw your application under this Offer. If you wish to withdraw your application for any reason (including if you change your mind about investing in the Company), you must do so within five business days of making your application (the Cooling-off Period).

You must withdraw your application via the Intermediary’s platform. You need to email [email protected] within five business days of making the pledge. Please include your full legal name, amount pledged and email address the pledge was registered under. 

After your withdrawal has been processed, your pledge will be cancelled and your pledge will not be processed. 

 

4.2 Communication facility for the Offer

You can ask questions about the Offer on the communication facility available on the Intermediary’s platform. You can also use the communication facility to communicate with other investors, with the Company and with the Intermediary about this Offer.

You will be able to post comments and questions about the Offer and see the posts of other investors on the communication facility. The Company and/or the Intermediary will also be able to respond to questions and comments posted by investors.

Officers, employees or agents of the Company, and related parties or associates of the Company or the Intermediary, may participate in the facility and must clearly disclose their relationship to the Company and/or Intermediary when making posts on the facility.

Any comments made in good faith on the communication facility are not subject to the advertising restrictions in the Corporations Act.

 

4.3 Proprietary company corporate governance obligations

4.3.1 Annual report 

While the Company is currently a small proprietary company that is not required to prepare annual financial reports and directors’ reports, if we successfully complete this Offer, then we will be required to prepare and lodge these annual reports with ASIC (within four months of the financial year end). The Company has a 30 June year end and its financial reports must be lodged by 31 October each year.

Our financial reports are currently not required to be audited as we are a small proprietary company. This means that the Company’s financial reports will not be subject to auditor oversight, and, therefore, there will be no independent assurance of the Company’s financial statements. However, the directors are still required to ensure that the financial statements give a true and fair view of the Company’s financial position and performance, and that the financial statements comply with the accounting standards.

We may be required to have our financial reports audited in the future if we raise more than $3 million from CSF offers (including this current offer and any future offers), or, otherwise, become a large proprietary company.

 

4.3.2 Distribution of annual report 

The Company is not required to notify shareholders in writing of the options to receive or access the annual report. Shareholders will not be able to elect to receive a copy of the annual report by way of email or post. However, shareholders can access the annual report on the Company’s website or can purchase the report from ASIC.

 

4.3.3 Related party transactions 

If we successfully complete this Offer, the rules on related party transactions in Chapter 2E of the Corporations Act will apply to the Company (for so long as we continue to have CSF shareholders). This means that the Company is required to obtain shareholder approval before giving financial benefits to related parties of the company (e.g. directors and their spouses, children or parents), subject to certain exceptions (such as reasonable remuneration provided to directors).

4.3.4 Takeovers 

If we successfully complete this Offer and have more than 50 shareholders, the takeover rules in the Corporations Act will only apply to the Company in a very limited way. If someone wants to buy more than 20% of the voting shares in the Company, they will be able to do so without complying with the takeover rules. This means that a person may be able to get control of the Company without making a formal takeover bid to all shareholders or without seeking shareholder approval.

Shareholders will not have the benefit of the full protections under the takeover rules, which means you may not have the right to vote on or participate in a change of control of the company. However, the general principles of ensuring shareholders have sufficient information and time to consider a change of control, and all have a reasonable and equal opportunity to participate in any benefits, will apply to the Company. In addition, the Takeovers Panel has jurisdiction to hear disputes relating to control of the Company.

 

 

Note from PledgeMe

We have completed background checks on the Medicinal Organic Cannabis Australia (MOCA) Pty Ltd (ACN: 619 709 278) and the Board of Directors (Alessandro Sorbello and Emanuela Ispani). We found no adverse findings in our checks. Please read the warning statement, offer document and ask questions before choosing to invest. PledgeMe will receive 6% (GST exclusive) of the funds raised, if the goal is met by the deadline. 

Updates 3

MOCA achieves its primary target 4 days before the deadline! Thank you to all who have pledged.

18/10/2020 at 5:45 AM

MOCA achieves it primary target 4 days before the deadline

Alessandro, Emanuela and all the team at MOCA are proud to announce that we have hit our primary target and are now funded. We owe it to you.. our beautiful crowd that believe in MOCA and our goal to be the most profitable and successful organic cannabis company in Australia. 

We are inspired by YOU our crowd and your belief in MOCA drives us to achieve our goals, starting with making medical cannabis products much more affordable for all Australian. 

Our next goal is to reach our maximum target of $500,000 over the next 4 days. 

We thank you for your support and ask that you help share our campaign in your networks, we believe that it is by word of mouth that others will also learn about MOCA and the investment opportunity currently on offer. Please share this link https://www.pledgeme.com.au/investments/35-medicinal-organic-cannabis-australia-moca-pty-ltd to your family, friends and colleagues who are interested in an investment opportunity that can also change lives for people in need of organic cannabis based medication. 

Thank you once again for taking this journey with us.

Our best regards to you our shareholders and inspiration.

Alessandro, Emanuela and all the team at MOCA

 

You need to pledge to see this update.

You need to pledge to see this update.

    Details

    Offer Details

    Current Valuation 15,010,000
    Raise Minimum 100,000
    Raise Maximum 500,000
    Share Price 1.00
    Maximum Shares Offered 500,000

    Company Documents

    Documents no longer available to download, as this campaign has closed

    Director Details

    Name Role Profile URL Invested?
    Alessandro Sorbello Director https://www.linkedin.com/in/alessandrosorbello/
    Emanuela Ispani Director https://www.linkedin.com/in/emanuela-ispani-1139935/

    Questions

    Ask a Question (You must login to ask a question)

    Pledgers 35

    Ryan
    2020-10-21 17:13:40 +1100

    "Looking Forward to the future of the cannabis industry in Australia."

    Renee Davidson
    2020-10-21 11:35:49 +1100
    Kerry boiko
    2020-10-21 08:44:12 +1100
    Sonja Nikolovski
    2020-10-21 08:29:06 +1100
    Daniel
    2020-10-21 07:58:46 +1100
    Ken Takano
    2020-10-20 22:07:59 +1100
    Roberto
    2020-10-20 19:16:19 +1100

    "Supporting Alessandro's vision and his project."

    Ireneo Guevara
    2020-10-20 03:19:52 +1100
    Francesca Schwarz
    2020-10-19 22:23:53 +1100
    Elena Ragonese
    2020-10-19 22:03:00 +1100

    "Happy to be part of the MOCO crowd pledge family "

    Anna Devlin
    2020-10-19 21:24:01 +1100
    Laura Vecchi-Cortese
    2020-10-18 23:03:24 +1100

    "Delighted to support Moca and its commitment in offering new options to support our health"

    Wendy Rice
    2020-10-18 08:25:16 +1100
    Mariel Donita P Guevara
    2020-10-17 11:28:38 +1100
    Frank
    2020-10-17 09:35:34 +1100
    Anton
    2020-10-17 05:06:26 +1100

    "MOCA is offering an opportunity that is head and shoulders above the competitors. One company to watch as the market grows"

    Kate White Rma
    2020-10-15 21:46:19 +1100
    Lisa Hunt
    2020-10-15 20:17:43 +1100
    Terry & Janette Bulmer
    2020-10-15 14:05:32 +1100

    "MOCA is considered to be a very positive initiative."

    Emma S
    2020-10-13 21:14:04 +1100

    "This Company is destined to become an industry giant."

    Zoe
    2020-10-10 13:52:58 +1100
    Dee Bounds
    2020-10-06 14:18:37 +1100

    "MOCA approaches this industry with integrity and professionalism. Looking forward to the inevitable success in the future of this organization."

    Emma GoodmanPledgeMe Staff
    2020-09-30 18:07:25 +1000
    Francis Tooman
    2020-09-27 10:59:25 +1000
    Kath
    2020-09-26 16:53:32 +1000
    Rachel
    2020-09-25 10:12:59 +1000
    Ireneo Guevara
    2020-09-24 13:36:16 +1000
    Charlie Steppa
    2020-09-24 08:20:27 +1000

    "I support the incredible hard work from the team at MOCA"

    Jaehkoeb Aarisenko
    2020-09-24 06:52:33 +1000

    "#legalizefreedom (medicinal, recreational, spiritual, and even industrial uses of marijuana/cannabis for one and for all: Life Is Beautiful)"

    Daniel O'Brien
    2020-09-24 01:54:38 +1000

    Followers 5

    Followers of Medicinal Organic Cannabis Australia (MOCA) Pty Ltd

    Medicinal Organic Cannabis Australia (MOCA) Pty Ltd

    Medicinal Organic Cannabis Australia (MOCA) Pty Ltd (ACN: 619 709 278) are offering up to 500,000 fully-paid ordinary shares at $1 per share to raise a maximum of $500,000. This Offer is made under the CSF regime in Part 6D.3A of the Corporations Act 2001 (Corporations Act).

    The general public in Australia can buy up to $10,000 worth of shares in this company, as part of the new equity crowdfunding legislation (Note: there is no cap on how much Sophisticated Investors can invest). Please make sure to read the risk warning statementoffer document, and understand the Cooling-Off rights. Instructions on how to register to invest and pledge are here.

     

    Whats in this for you, the investor?

    In this proposal, you will find an opportunity to invest in a highly profitable business model designed to bring high yield dividends to YOU the investor. Our focus is in developing rapid and significant capital growth with a view to going public in the next 2/3 years. Our plan is to dominate the organic cannabis industry in Australia. 

    What makes us different and why we will succeed!

    Investing in MOCA means backing a company that has a unique delivery model to bring cannabis medication to the broader market, making it accessible to the largest possible customer base. Our operational structure and product sourcing allows MOCA to disrupt the industry in Australia by bringing best quality products at the lowest prices. We do this through our low operating costs, agility to respond to a rapidly changing market dynamic and leveraging state of the art third party logistics fulfilment systems. Backing MOCA is backing a winning team dedicated to success.

    Letter from the Co-founder, Alessandro Sorbello

    Dear friends and potential investors,

    We are very excited about the information we are about to share with you. Medicinal Cannabis is a booming industry and it's still in its infancy.

    And now a little about how we got to where we are and our plans for ongoing profitable growth.

    Health, wellbeing and quality of life has been a central theme in my life and in recent years, much more so. When my father was in his 20’s he suffered from a major head trauma as a result of a motorcycle accident. This led to mental health issues late in his life. As one of his principal carers during the last ten years of his life, it was saddening to witness firsthand the deterioration of his memory and many other mental faculties.

    It was not until after his passing in 2014, that I came to learn that the United States government had patented cannabis as a neuroprotectant in the 1980’s. The patent claims: “...cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia”.

    My father's passing left me wondering how cannabis may have been able to help him and increase his quality of life, in particular, late in his life when his dignity began to suffer. I wondered why the medication that would have surely helped him was not available.

    When the Australian Government announced in 2016 that it was changing legislation regarding cannabis, I started to delve into it much further. I learned that cannabis is an ancient medicine with well over 7000 years of history. In the 21st century, after a hiatus of over 70 years due to prohibition, it has once again become a recognised medicine, rapidly gaining in popularity around the world because of its effectiveness.

    As a PhD candidate, I am used to conducting research and very early on I learned a key fact regarding cannabis. Something so startling, that it would set my destiny on a new and exciting path and I owe it all to an Israeli scientist named Raphael Meschulam.

    Professor Meschulam discovered in 1990 that humans and almost all animals have an endocannabinoid system (ECS) that responds favourably to cannabis. The ECS is considered among the most important systems in the human body and is responsible for maintaining and regulating health. Reference

    The importance of this information captured my attention so much, that I dove into learning everything I could about the ECS and how cannabis functions as a medicine. Armed with this information and glimpsing what this would mean for humanity, my partner Emanuela and I committed to revolutionise our lives and our professional activities. We both recognised that this was the opportunity we were looking for.

    As company directors and founders, Emanuela and I both have a long history of building teams and organisations to set new boundaries on how ethical business is conducted. I spent 11 years with the Italian Ministry of Foreign Affairs as a Cultural Attache’. In 2010 I was honored to be awarded a Knighthood by the President of Italy for my work on building international trade between Italy and Australia. Emanuela spent numerous years as an advisor to the Department of Justice in Queensland, reporting directly to the Minister.

    Emanuela and I placed our focus entirely on the emerging medical cannabis industry. We undertook intensive learning and study to grasp the potential of the healing plant and the business opportunity it presented.

    Analysts indicate that Australia’s cannabis market is expected to surpass the US$1.5 billion mark by 2025, making it the largest legal cannabis market in the Oceania region. Reference. International projections indicate the global cannabis market size will reach US$97.35 billion by the end of 2026, up from US$10.6 billion in 2018. Reference.

    With our vision becoming clearer each week and month, and with the business world confirming the enormous and rapid growth of the cannabis market worldwide, we started assembling a larger team. To build our advisory board, we enlisted Dr Arno Hazekamp, one of the world's leading experts on medical cannabis research. Next, we engaged Dr Eliane Karsaklian to our advisory board, a senior professor at the Sorbonne University who is an expert of international business & negotiations for over 20 years.

    This combination of scientific expertise and extensive international business experience formed the basis of our company, Medicinal Organic Cannabis Australia. We like to call it MOCA. We chose to incorporate the word organic into the name of the company because we believe that pesticides and herbicides have no place in medicine.

    The cornerstone philosophy of MOCA is ‘People, Planet, Profit’ and one of MOCA’s key metrics for success is our ability to make cannabis medication affordable. We believe that a plant based medicine should be available to everyone.

    Over the past three years since MOCA was established, we have taken many important and exciting steps forward toward our vision and our goals.

    Today, MOCA is an Australian Government licenced medical cannabis importer, exporter and wholesaler. The Company’s licences were awarded by the Australian State and Federal Governments in 2018. These licences allow the Company to manufacture, import and supply by wholesale medical cannabis products. Our Government approved client base consists of hospitals, pharmacies and medical practitioners. The Company's complete product range is approved by the Therapeutic Goods Administration (TGA) and is ready for practitioners to prescribe to patients in Australia. Our approved medical cannabis product range includes capsules, sublingual oils, isolates, vape pens and whole cannabis flowers. We currently hold all necessary permits from the Office of Drug Control (ODC) to import medical cannabis products into Australia.

    Through our ‘hands on’ approach, we have created an innovative way to lower the product cost to patients by up to 30% of current retail prices. We have also been working directly with cultivators to positively influence and improve the methodology of the organic farming practices.

    We are very proud of what we have achieved so far and are very excited about the journey that’s unfolding before us, that continually brings our vision to existence. We trust that you will enjoy our presentation and decide to own a piece of MOCA, to continue this journey with us.

    We are at a new beginning in plant-based medicine.

    Thank you and warm regards

    Alessandro

     

     

     

    Our products

    MOCA offers a wide range of organic medical cannabis products imported from the United States and Europe with shipments due to arrive in Australia in November/December 2020. The range of products includes organic capsules, oils, tinctures and cannabis flowers with THC, CBD and a combination of both. The Company is licenced to import, export and wholesale the full spectrum of medical cannabis products including THC and CBD products. Overall, MOCA meets the highly regulated medical cannabis needs of Australian regulators and International patients, medical doctors, pharmacies and hospitals.

    Our CBD products are made from 100% organically grown, non-GMO Hemp. Cultivated premium grade, pesticide-free, heavy metal-free, solvent-free, gluten-free, THC-free, FDA-registered, cGMP-certified, ISO 9001, ISO 17025, industrial hemp registered, and 3rd-Party Tested.

    MOCA holds permits from the Office of Drug Control to import our full  range of 21 products including: 

    Products

    Concentration and Size

    CBD Oil Capsules 

    750mg

    Hemp and MCT Oil

    500mg, 1000mg, 1500mg

    CBD Flowers

    5 grams, 10 grams, 28 grams

    THC & CBD Flowers

    10grams

    MOCA CBD Capsules Full Spectrum

    25mg

    MOCA CBD DROPS 

    1000mg, 1500mg, 3500mg, 5000mg

    MOCA CBD Isolates

    99% and 99.88% CBD

    Vape Pens

    5ml

    CBD Tinctures

    60mg, 120mg, 300mg, 500mg

     

    In order to ensure continuity of supply in potential times of limitations on product movement, we have multiple suppliers for each of our products. In the event of disruption in the supply chain, we are able to import our products, made to our specifications from different manufacturers and geographical locations. 

    
MOCA has developed a new product sourced directly from growers in the Mediterranean that has the potential to reduce costs to patients by up to 30%.



    The product range is all organic and naturally produced and takes advantage of the ‘entourage effect’ by using all the cannabinoids in the whole plant. At this stage, we are keeping the technical details confidential to ensure we can leverage the product to be first movers in the Australian industry.

     

     

    Our business model

    MOCA’s business model is built on quality, agility, market responsiveness and economy of scale in bringing our products to market. Our team comprises dedicated professionals with over 40 years’ experience in the cannabis industry and the Company is committed to educating consumers and health professionals on the use of medical cannabis.

    Our business model is very simple and is described in two parts. We: 

    1) Import and wholesale our products

    2) Source, control production and manufacture high quality products.  

     

     

    1) Importing and wholesaling our products 

    Part one includes all the activities associated with importing. selling and distribution of our products and reaching customers to transacting a sale. In this phase of product distribution another factor comes into play. As a wholesaler our facility  breaks products down into smaller units, which are then sold to different medical retailers.

    This process is handled for MOCA by a contracted, specialised pharmaceutical grade third party supplier which means we have lower costs. 

    In addition to critical sales and marketing skills, we believe MOCA has the operational skills necessary for running the Company. Our finance and business management skills and experience give us the  ability to handle the "back end" that go on behind the scenes, like receiving customer orders and providing high levels of customer service. We are technology driven and have automated many of the processes with third party digital software for accounting, ordering and managing inventory.

     

     

    2) Source, control production and manufacture high quality products. 

    The cornerstone in our distribution cycle is the basic flow of product from manufacturer to distributor to customer. As a wholesale distributor, our role on the supply chain involves matching up manufacturers  and customers by obtaining quality products at a reasonable price and then selling them to the companies that need them.

    Part two comprises all the manufacturing and sourcing phases. This includes all the activities associated with making and designing our products, including purchasing raw materials, manufacturing, and so on. 

    In this phase, we use our team's expert knowledge of the industry to work with growers and cultivators and choose which crops and products we are interested in acquiring. 

    Our focus on the ‘Triple Bottom Line’ of ‘People, Planet, Profit’ means that we work with designers, growers, scientists and manufacturers aligned to our principles to create our organic range of cannabis medicines.

    Our directors work hands on and ‘boots on the ground’  to select suppliers that meet our Triple P processes. These cultivators grow organically and ethically and have developed trust in our relationship. This means that we are not only a reliable source for customers but can be a reliable source for the industry. 

    Some of the most affordable products for retail sales come from other countries where product development and manufacturing is more advanced than Australia. Importing is the best option for getting the products that meet our criteria of high quality and affordable prices. By dealing with multiple suppliers we can buy products at their best to sell directly to the medical industry at a good margin.

    Since obtaining our Federal licences, the Company has concentrated on developing high quality, organic products to supply under the MOCA brand. Our business intelligence team, in conjunction with the University of Paris (Sorbonne) conducted a 12 month long extensive consumer survey to understand patient needs. In 2019/2020 we extended this ongoing research by working with medical practitioners in Australia to understand how doctors are prescribing cannabis. Our scientific research team developed our products based on client and prescriber requirements.  

    Now that we have all of our licences, we are ready to expand our importation into Australia to our complete range of high quality organic products specifically designed to meet growing medical practitioners prescribing demand.  

     

     

    Our team

    Company Directors 

    Alessandro Sorbello

    Alessandro Sorbello PhD candidate (Managing Director) has been a company director for over 30 years. He holds a Masters degree in Business and is completing his PhD on Consumer Behaviour. His roles have included Secretary General of the Italian Chamber of Commerce and Cultural Attaché to the Italian Ministry of Foreign Affairs.  He is an international award winning researcher and publisher. Read More 

    Emanuela Ispani

    Emanuela Ispani  BE (Electronics) (Director) holds a degree in electronics engineering, specialised in Robotics.  Her expertise includes business management, strategy development, research, and business planning. She has extensive experience in working with both State and Federal Government reporting to the Minister. Her work within the Information Technology industry, at national and international levels has been a progression from business consulting to project/program management. Read More 

    Scientific Advisory Team

    Arno Hazekamp

    Head of Scientific Research - Dr Arno Hazekamp PhD is an internationally acclaimed cannabis researcher biochemist, and former Head of Research and Education at Bedrocan BV - the official grower of medicinal cannabis in the Netherlands. His PhD thesis was focused on the medicinal use of cannabis, and the practical issues that prevent it from becoming part of modern medicine. He is a board member of the International Association for Cannabinoid Medicines (IACM), an active international lecturer and medicinal cannabis advocate. Read More 

    Eliane Karsaklian

    Head of International Marketing - Dr Eliane Karsaklian PhD is an internationally known speaker, award-winning researcher, and professor who directs the Master Program for International Negotiation at Université Sorbonne in Paris. She has led several companies including Discovery Channel, Gucci, Sanofi-Aventis and Walt Disney World to build relationships that created or expanded their markets. She has published several articles and books in the field of international business more recently Sustainable Negotiation. Read more

    Alessandra Scano

    Scientific Research - Dr. Alessandra Scano PhD holds a Master in Science degree in Pharmaceutical Chemistry and Technology and a PhD in Chemical Science. She also has a  Master in Science in Cellular and Molecular Biology at University of Cagliari. She spent one year (2009) as Postdoc at Materials and Surface Science Institute (MSSI), University of Limerick (Ireland). Read More

    Guido Ennas

    Scientific Research -Professor Guido Ennas PhD. is the Deputy Director of the Biology and Pharmacy Faculty, and Leader of the Micro and Nanostructured Materials Research Group, being a specialist in design, synthesis, characterization (structural, morphological and thermal) and developing of inorganic, nanostructured micro and mesoporous materials. Read More

    Finance

     Joe Catalano

    Head of Finance - Joe Catalano Bachelor of Commerce Joe is the director and Founding Partner of CNS Partners the company has 4 directors and 10 team members. As founding partner, Joe has been involved from the early humble beginnings, to the successful, multi-faceted organisation his clients currently enjoy. Joe has a Bachelor of Commerce, a Graduate Diploma of Chartered Accounting (CA), is a registered tax agent and holds a public practice certificate. Read More

     

    Our Growth Plans

    Over the next three years, the Company will operate on a staged approach to leverage its licences and continue to bring a variety of federally approved medical cannabis products into Australia.

    Stage one is manufacturing and importing our approved range of products to sell to a rapidly growing market. We plan to leverage the very recent changes to legislation to take rapid advantage by marketing the 4 products in our product range that meet the new regulations and that are already approved by the TGA. 

    Manufacturing our Medicine

    Stage two is manufacturing our newest range of whole plant infusion products. We believe this is a game changer for the industry as we have developed a product that will significantly reduce the cost of the medicine. We have access to a large supply of organically grown whole plant biomass that we can acquire at excellent prices. We plan to flood the Australian market with this new product in late 2020. To give you some idea of how excited we are by this new product, CBD flowers on the wholesale market in Australia sell to the end user for approx $120 for 10 grams.

    Our new product could be on the market for $120 for 100 grams. 

    We believe this is a true game changer. 

     

     

    Stage three is operationalizing our cultivation facility in Italy. The Company has signed a 15 year lease agreement for 18,000m2 of high quality organic agricultural land. The property has a purpose built 6900m2 Greenhouse ideal for organic cannabis cultivation. Our approved subsidies  allow MOCA to purchase fuel necessary to run equipment at 50% of retail prices.  These subsidies allow the Company to produce cannabis biomass at substantially reduced costs in comparison to cultivation  in Australia.  We anticipate being able to produce over 10,000 kgs of organic whole plant biomass, rich in CBD for importation into Australia in 2021. 

    At this stage we will cultivate cannabis rich in CBD and complete the entire cycle: cultivation, manufacturing, importing and wholesaling. 

    Our import licences enable us to wholesale our cannabis products to pharmacies, hospitals and licenced medical professionals. Our export licence enables the Company to sell products to licenced buyers around the world.

    Our potential import sales for 2020-2023

    Our average unit will cost $32.00 to produce, and wholesale at $115.00. 

     

    Expand Digital Marketing

    Our marketing focus is online and MOCA has on average over 35,000 visitors per month to its online presences. Our Google My Business performance of 25,900 views in a 28 day period. We will be expanding the site with our range of products and promoting our partner pharmacies and medical practitioners. We intend to expand our marketing online by further developing our online brands which include the MOCA website on www.medicinalorganiccannabis.org. MOCA has developed an online sales platform (full product range and pricing to be added when products are ready for purchase) for sales directly to the pharmaceutical industry.

    We have a basic presence on our other websites which include https://www.OrganicCBD.com.au and this will be expanded to include our product range. The site will be optimised for SEO and will offer the entire suite of services offered on the MOCA site. 

    Our visibility on  the major search engines is very high as you can see from the Google search results for ‘organic cannabis Australia’. Our focus will be on expanding the online presences across all sites including social media. The Company will develop secondary search engines results including medicinal organic cannabis on Yahoo (first page listing)

    These are a small selection of our brand building online that MOCA has been developing over the past 3 years. 

    Our digital strategy is high on our priorities to leverage our current visibility and attract new patients, medical practitioners and pharmacies.

    MOCA has a definite focus on a global market, the Company has already participated in 2 international tenders to supply markets in Italy and Barbados. Our approach to penetrating national and international markets leverages our experience in online marketing. The Company enjoys the very high visibility online via our numerous digital marketing channels as you will see later in this presentation. In effect, we receive several requests from practitioners and pharmacies each day for supply of our products.

     

     

    Our Capital Structure

    As at the date of this CSF offer document, the Company has 15,010,000 Class A shares. As set out in Table 1 below, the 15,000,000 shares are held by two of the Company’s Executive Directors, Mr Alessandro Sorbello (Managing Director) and Ms Emanuela Ispani (Executive Director), and Mr Peter Cupples and Ms Lisa Cornish also have 5,000 shares each.

     

     

    Our Risks

    An investment in the Company should be seen as high-risk and speculative. A description of the main risks that may impact our business is below. Investors should read this section carefully before deciding to apply for shares under the Offer. There are also other, more general, risks associated with the Company (for example, risks relating to general economic conditions or the inability to sell our shares). We have worked hard to mitigate our risks: 

     

    Licencing and government approvals 

    The Company has already obtained all the necessary import/export licences and licences to sell prohibited drugs approvals from the Office of Drug Control (ODC). We currently hold licences from New South Wales Health to store and handle all cannabis based medications and have an approved set of protocols to manage logistics, warehousing and distribution. The ODC has already issued MOCA with import permits to bring our products into Australia. Starting with the products that are most in demand and taking advantages of the recent changes to legislation regarding CBD, we will import products to match these profiles (e.g. capsules, vapes, cbd oils)

    TGA Approvals 

    The Therapeutic Goods Administration (TGA) must approve all medical cannabis products in Australia. Currently MOCA has 21 products approved by the TGA for prescription to patients by medical practitioners.

    Customer Base

    Numerous medical practitioners, hospitals and pharmacies seeking our products. These clients are awaiting our medicines to be imported for prescribing to their patients 

    Patient Intake Program

    The Company has a patient intake program whereby patients contact MOCA seeking our medications and assistance in obtaining access to medical practitioners.

     

    Main risks

    There are still many potential risks to the business that include: 

    Increased Competition 

    The cannabis industry in Australia and internationally is growing rapidly with increased competition entering into the market.  Local production is ramping up and in the coming years will produce a significant output of plant biomass ready for transformation into finished products. MOCA is offsetting some of this risk by working with international markets for supply and in the second instance for export from Australia. The Company is currently working in the European market that has a potential customer audience of 740 million people

    Market Growth Plateaus

    Medical cannabis growth in Australia has risen consistently and access has become easier for patients. In the future, growth in the marketplace may stabilise and growth may stall. MOCA offsets this risk by diversifying our potential audience with differentiated price points of organic and non-organic products.

    Present Sources of Product Supply

    MOCA has supply agreements with OrganicMarijuana.com, an international wholesaler and cultivator of organic cannabis as well as with organisations in the United States, Jamaica, Italy and Canada.

    We have supply agreements with multiple suppliers in the event of disruption to our supply chain. These suppliers are located in various countries, limiting the risk of supply disruption.  Our intention is to keep a supply of 1500 units of stock in Australia at all times, in the event that there is a disruption to supply due to Covid 19 or other potential threats. This supply will ensure continuity of stock in the event that we are required to ramp up manufacture from another supplier. 

    Future competition

    The Australian medical cannabis industry is still in its infancy and local demand will continue to outweigh local supply for many years to come. Given the variations of cannabis-based medications and the increase in demand for organic medicine, MOCA is well positioned to capitalise on the growing market in Australasia 

    Import restrictions affecting products

    Medical cannabis currently falls under both schedule 4 and schedule 8 classifications by the TGA and the Office of Drug Control and is a highly regulated medicine. MOCA is one of only 26 companies licenced to import cannabis-based products into Australia (3). Obtaining licences for import and export in Australia is costly and approvals can take up to 18 months.   Of the 100 products approved by the Federal government, MOCA has 21 products already approved. 

    Growth in competition from black market products

    In the past, many patients have turned to the illegal black market to obtain cannabis for treatment of medical conditions, due to the long approval times and the high cost of legally available products. The changes in legislation and the increased supply in legal options has seen rapid growth in demand.   

    Cashflow

    There is a risk that the company may not be able to access capital. This could affect cash flow issues as MOCA grows. Our business strategy to mitigate this risk is to import and sell our products immediately to establish a revenue stream. Our Aim is that ongoing sales from continually arriving imported stock will generate the cashflow necessary to grow and keep the company secure.

     

     

     

     

    Our Offer

    The Company is offering up to 500,000 shares at an issue price of $1 to raise up to $500,000. 

    Key information relating to the offer is set out below.

    _____________

    Term Details 

    _____________

    Shares: Fully paid ordinary shares

    Price: $1 per share

    Minimum Subscription: $100,000

    Maximum Subscription: $500,000

    Opening Date: 21st September 2020

    Closing Date: 21st October 2020

    _____________

     

    A description of the rights associated with the shares is set out in Section 3.3 of our offer document. To participate in the Offer, you must submit a completed application form via the Intermediary’s platform. The Intermediary’s website provides instructions on how to apply for shares under the Offer. 

     

    The Intermediary must close the Offer early in certain circumstances. For example, if the Maximum Subscription is reached, the Offer must be closed. If the Minimum Subscription is not reached or the Offer is closed but not completed, you will not be charged for your pledge. Investors may withdraw their application during the Cooling-off Period. 

     

    Further information on investor cooling-off rights can be found in Section 4 of this CSF offer document. 

     

    The Offer is not underwritten.

     

     

    Information about Investor Rights

    4.1 Cooling-off rights 

    You have the right to withdraw your application under this Offer. If you wish to withdraw your application for any reason (including if you change your mind about investing in the Company), you must do so within five business days of making your application (the Cooling-off Period).

    You must withdraw your application via the Intermediary’s platform. You need to email [email protected] within five business days of making the pledge. Please include your full legal name, amount pledged and email address the pledge was registered under. 

    After your withdrawal has been processed, your pledge will be cancelled and your pledge will not be processed. 

     

    4.2 Communication facility for the Offer

    You can ask questions about the Offer on the communication facility available on the Intermediary’s platform. You can also use the communication facility to communicate with other investors, with the Company and with the Intermediary about this Offer.

    You will be able to post comments and questions about the Offer and see the posts of other investors on the communication facility. The Company and/or the Intermediary will also be able to respond to questions and comments posted by investors.

    Officers, employees or agents of the Company, and related parties or associates of the Company or the Intermediary, may participate in the facility and must clearly disclose their relationship to the Company and/or Intermediary when making posts on the facility.

    Any comments made in good faith on the communication facility are not subject to the advertising restrictions in the Corporations Act.

     

    4.3 Proprietary company corporate governance obligations

    4.3.1 Annual report 

    While the Company is currently a small proprietary company that is not required to prepare annual financial reports and directors’ reports, if we successfully complete this Offer, then we will be required to prepare and lodge these annual reports with ASIC (within four months of the financial year end). The Company has a 30 June year end and its financial reports must be lodged by 31 October each year.

    Our financial reports are currently not required to be audited as we are a small proprietary company. This means that the Company’s financial reports will not be subject to auditor oversight, and, therefore, there will be no independent assurance of the Company’s financial statements. However, the directors are still required to ensure that the financial statements give a true and fair view of the Company’s financial position and performance, and that the financial statements comply with the accounting standards.

    We may be required to have our financial reports audited in the future if we raise more than $3 million from CSF offers (including this current offer and any future offers), or, otherwise, become a large proprietary company.

     

    4.3.2 Distribution of annual report 

    The Company is not required to notify shareholders in writing of the options to receive or access the annual report. Shareholders will not be able to elect to receive a copy of the annual report by way of email or post. However, shareholders can access the annual report on the Company’s website or can purchase the report from ASIC.

     

    4.3.3 Related party transactions 

    If we successfully complete this Offer, the rules on related party transactions in Chapter 2E of the Corporations Act will apply to the Company (for so long as we continue to have CSF shareholders). This means that the Company is required to obtain shareholder approval before giving financial benefits to related parties of the company (e.g. directors and their spouses, children or parents), subject to certain exceptions (such as reasonable remuneration provided to directors).

    4.3.4 Takeovers 

    If we successfully complete this Offer and have more than 50 shareholders, the takeover rules in the Corporations Act will only apply to the Company in a very limited way. If someone wants to buy more than 20% of the voting shares in the Company, they will be able to do so without complying with the takeover rules. This means that a person may be able to get control of the Company without making a formal takeover bid to all shareholders or without seeking shareholder approval.

    Shareholders will not have the benefit of the full protections under the takeover rules, which means you may not have the right to vote on or participate in a change of control of the company. However, the general principles of ensuring shareholders have sufficient information and time to consider a change of control, and all have a reasonable and equal opportunity to participate in any benefits, will apply to the Company. In addition, the Takeovers Panel has jurisdiction to hear disputes relating to control of the Company.

     

     

    Note from PledgeMe

    We have completed background checks on the Medicinal Organic Cannabis Australia (MOCA) Pty Ltd (ACN: 619 709 278) and the Board of Directors (Alessandro Sorbello and Emanuela Ispani). We found no adverse findings in our checks. Please read the warning statement, offer document and ask questions before choosing to invest. PledgeMe will receive 6% (GST exclusive) of the funds raised, if the goal is met by the deadline. 

    MOCA achieves its primary target 4 days before the deadline! Thank you to all who have pledged.

    18/10/2020 at 5:45 AM

    MOCA achieves it primary target 4 days before the deadline

    Alessandro, Emanuela and all the team at MOCA are proud to announce that we have hit our primary target and are now funded. We owe it to you.. our beautiful crowd that believe in MOCA and our goal to be the most profitable and successful organic cannabis company in Australia. 

    We are inspired by YOU our crowd and your belief in MOCA drives us to achieve our goals, starting with making medical cannabis products much more affordable for all Australian. 

    Our next goal is to reach our maximum target of $500,000 over the next 4 days. 

    We thank you for your support and ask that you help share our campaign in your networks, we believe that it is by word of mouth that others will also learn about MOCA and the investment opportunity currently on offer. Please share this link https://www.pledgeme.com.au/investments/35-medicinal-organic-cannabis-australia-moca-pty-ltd to your family, friends and colleagues who are interested in an investment opportunity that can also change lives for people in need of organic cannabis based medication. 

    Thank you once again for taking this journey with us.

    Our best regards to you our shareholders and inspiration.

    Alessandro, Emanuela and all the team at MOCA

     

    You need to pledge to see this update.

    You need to pledge to see this update.

      Offer Details

      Current Valuation 15,010,000
      Raise Minimum 100,000
      Raise Maximum 500,000
      Share Price 1.00
      Maximum Shares Offered 500,000

      Company Documents

      Documents no longer available to download, as this campaign has closed

      Director Details

      Name Role Profile URL Invested?
      Alessandro Sorbello Director https://www.linkedin.com/in/alessandrosorbello/
      Emanuela Ispani Director https://www.linkedin.com/in/emanuela-ispani-1139935/

      Ask a Question (You must login to ask a question)

      Followers of Medicinal Organic Cannabis Australia (MOCA) Pty Ltd

      Ryan
      2020-10-21 17:13:40 +1100

      "Looking Forward to the future of the cannabis industry in Australia."

      Renee Davidson
      2020-10-21 11:35:49 +1100
      Kerry boiko
      2020-10-21 08:44:12 +1100
      Sonja Nikolovski
      2020-10-21 08:29:06 +1100
      Daniel
      2020-10-21 07:58:46 +1100
      Ken Takano
      2020-10-20 22:07:59 +1100
      Roberto
      2020-10-20 19:16:19 +1100

      "Supporting Alessandro's vision and his project."

      Ireneo Guevara
      2020-10-20 03:19:52 +1100
      Francesca Schwarz
      2020-10-19 22:23:53 +1100
      Elena Ragonese
      2020-10-19 22:03:00 +1100

      "Happy to be part of the MOCO crowd pledge family "

      Anna Devlin
      2020-10-19 21:24:01 +1100
      Laura Vecchi-Cortese
      2020-10-18 23:03:24 +1100

      "Delighted to support Moca and its commitment in offering new options to support our health"

      Wendy Rice
      2020-10-18 08:25:16 +1100
      Mariel Donita P Guevara
      2020-10-17 11:28:38 +1100
      Frank
      2020-10-17 09:35:34 +1100
      Anton
      2020-10-17 05:06:26 +1100

      "MOCA is offering an opportunity that is head and shoulders above the competitors. One company to watch as the market grows"

      Kate White Rma
      2020-10-15 21:46:19 +1100
      Lisa Hunt
      2020-10-15 20:17:43 +1100
      Terry & Janette Bulmer
      2020-10-15 14:05:32 +1100

      "MOCA is considered to be a very positive initiative."

      Emma S
      2020-10-13 21:14:04 +1100

      "This Company is destined to become an industry giant."

      Zoe
      2020-10-10 13:52:58 +1100
      Dee Bounds
      2020-10-06 14:18:37 +1100

      "MOCA approaches this industry with integrity and professionalism. Looking forward to the inevitable success in the future of this organization."

      Emma GoodmanPledgeMe Staff
      2020-09-30 18:07:25 +1000
      Francis Tooman
      2020-09-27 10:59:25 +1000
      Kath
      2020-09-26 16:53:32 +1000
      Rachel
      2020-09-25 10:12:59 +1000
      Ireneo Guevara
      2020-09-24 13:36:16 +1000
      Charlie Steppa
      2020-09-24 08:20:27 +1000

      "I support the incredible hard work from the team at MOCA"

      Jaehkoeb Aarisenko
      2020-09-24 06:52:33 +1000

      "#legalizefreedom (medicinal, recreational, spiritual, and even industrial uses of marijuana/cannabis for one and for all: Life Is Beautiful)"

      Daniel O'Brien
      2020-09-24 01:54:38 +1000
      This campaign was successful and got its funding on 21/10/2020 at 7:00 PM.

      This campaign has closed, but this company may choose to do more equity raises on PledgeMe in the future. If you're interested in investing in Medicinal Organic Cannabis Australia (MOCA) Pty Ltd, you can sign up to be notified when a new equity campaign from this company is published.

      Notify Me

      Investor Perks

      15% Discount On CBD Medication

      AU $1,000.00+

      FOR THE FIRST 50 PLEDGES - With a prescription from a medical practitioner, and through our partner pharmacies - we will offer you a discount of 15% off the Recommended Retail Price off our in stock products for as long as you are a shareholder in MOCA

      Discounted CBD Medication

      AU $10,000.00+

      With a prescription from a medical practitioner, and through our partner pharmacies - we will offer you a discount of 20% off the Recommended Retail Price off our in stock products for as long as you are a shareholder in MOCA 

      Warning Statement

      Crowd-sourced funding is risky. Issuers using this facility include new or rapidly growing ventures. Investment in these types of ventures is speculative and carries high risks.

      You may lose your entire investment, and you should be in a position to bear this risk without undue hardship.

      Even if the company is successful, the value of your investment and any return on the investment could be reduced if the company issues more shares.

      Your investment is unlikely to be liquid. This means you are unlikely to be able to sell your shares quickly or at all if you need the money or decide that this investment is not right for you.

      Even though you have remedies for misleading statements in the offer document or misconduct by the company, you may have difficulty recovering your money.

      There are rules for handling your money. However, if your money is handled inappropriately or the person operating this platform on which this offer is published becomes insolvent, you may have difficulty recovering your money.

      Ask questions, read all information given carefully, and seek independent financial advice before committing yourself to any investment.